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treatment patterns, and marginal structural models (MSMs).
MSMs utilize all of the data, account for the treatment switch-
ing, while adjusting for selection bias and patient dropout.
RESULTS: Over 25% of 664 randomized patients switched
treatments during the study, 7% augmented their randomized
treatment, and another 28% discontinued early. Switching was
greatest among patients randomized to conventional anti-
psychotics (45% switched to atypicals, <20% of atypical patients
switched therapies). Treatments did not differ in BPRS total score
using various intent-to-treat analyses including last-observation-
carried-forward. However, MSMs and other approaches that
took into account the treatment switching demonstrated statis-
tically signiﬁcantly greater symptom reduction for patients
treated with olanzapine as compared to conventional anti-
psychotics (overall treatment difference: 4.2 points, p = 0.007).
CONCLUSIONS: Drawing inferences on treatment effects in
longitudinal naturalistic studies is challenging due in part to
patients changing or stopping medications over time. In this
study, standard methods did not address treatment effectiveness,
while MSMs provided a framework for addressing effectiveness
in the presence of switching, selection biases, and early dropout.
The MSM analysis showed olanzapine to be superior to con-
ventional anti-psychotics in reducing schizophrenic symptom
severity.
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OBJECTIVES: The study was conducted to examine following
hypotheses: Tricyclic Antidepressants (TCAs) use increases the
risk of colorectal cancer. In particular, the use of genotoxic TCAs
increases the risk as compared to non-genotoxic TCAs. The use
of Selective Serotonin Reuptake Inhibitors (SSRIs) decreases the
risk of colorectal cancer. METHODS: A population-based nested
case-control study was conducted using source population who
individually participate in the Saskatchewan Prescription Drug
Plan aged 5–82.5 years from 1981–2000 with no previous
history of cancer since 1967. A total of 6544 histologically
proven invasive colorectal cancer patients were identiﬁed from
the Saskatchewan Cancer Registry. For each case, four eligible
non-cancer controls matched on age, gender and calendar time
were randomly selected. The effects of antidepressant use were
examined by conditional logistic regression, considering dosage,
duration and timing of antidepressant use. RESULTS: A signiﬁ-
cant increased risk of colorectal cancer was observed for medium
dose and duration of TCAs use during 16–20 year period pre-
ceding diagnosis without signiﬁcant dose-response effect (Inci-
dence rate ratio (RR) for dose = 1.51, 95% conﬁdence interval
= (1.09–2.09); RR for duration = 1.60 (1.13–2.27)). No signiﬁ-
cant increased risk was observed among users of genotoxic
TCAs, while a signiﬁcantly increased risk was observed among
persons exposed to medium duration of non-genotoxic TCAs
during 16–20 years preceding diagnosis without signiﬁcant dose-
response effect (RR = 1.89 (1.14–3.14)). Signiﬁcant decreased
risk of colorectal cancer was observed among subjects heavily
exposed to SSRIs during 5-year periods preceding diagnosis (RR
for dosage = 0.62 (0.43–0.90), P-value of test for trend = 0.01;
RR for duration = 0.71 (0.50–1.00), P-value of test for trend =
0.008). CONCLUSIONS: No sufﬁcient evidence supporting that
the use of TCAs increases the risk of colorectal cancer. Our
results support the priori hypothesis that the use of SSRIs
decreases the risk of colorectal cancer.
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OBJECTIVE: To deﬁne a method of recognizing inﬂuence 
of comorbid conditions when studying outcomes of a speciﬁc
disease or therapy. Background: Patients are often suffering from
multiple disease states. When looking at resource utilization,
absenteeism, and other outcomes for a speciﬁc disease state or
therapy it is important to recognize the inﬂuence of other dis-
eases to the total costs and outcomes of the disease of interest.
METHODS: Several comorbidity indexes have been developed.
Well known and described are the Charlson Index with adapta-
tions, Index of Coexistent Disease, Cumulative Illness Rating
Scale, Chronic Disease Score and several other disease speciﬁc
indexes. The typical use of these indexes is predictive, a forecast
of mortality or costs based on the current history of a patient.
Many of these indexes require clinical information. The focus of
the current index is strictly toward administrative (claims) data-
bases. RESULTS: The methodology presented here is a nonlin-
ear transformation of the number of comorbid conditions, scaled
so that the probability of signiﬁcant comorbidity increases
monotonically with the number of conditions reported. This
AHRQ Comorbidity Index algorithms described by Elixhauser
are used to deﬁne a set of 31 comorbid conditions as deﬁned by
1111 ICD9 diagnoses. Sensitivity analysis of the number of
expected conditions resulted in a denominator of ten units.
CONCLUSIONS: The denominator to yield a percentage of
costs, outcomes, etc attributable to the comorbid conditions
divides the number of Elixhauser conditions, other than the
disease of interest. This index takes advantage of the longitudi-
nal nature of claims data to be inclusive of all disease states
within a patient and not just the current cause for treatment. It
provides an alternative approach to assign costs, absenteeism,
and other outcomes to a disease state that is a more accurate val-
uation of the outcomes without undue inﬂuence from other
comorbidities.
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OBJECTIVES: Inferring disease descriptions (e.g. asthma, mul-
tiple-sclerosis, etc) in a patient from his/her pharmacy proﬁle is
important in several sectors of health care such as insurance and
medical management. While the inference is relatively straight
forward in a few cases (e.g. diabetes in the presence of insulin),
very often the relationships are multifactorial. Manual, expert-
based processes for the task are unscalable and unmaintainable.
An automated, scalable and accurate method to infer disease
descriptions from a patient’s pharmacy proﬁle is the objective of
this study. METHODS: A large managed care database com-
prised of both medical and pharmacy claims was used for the
implementation. The pharmacy proﬁles were abstracted into
dummy variables based on First Data Bank drug classiﬁcation.
One dummy variable for each disease description based on
medical claims was created, and there were as many dummy vari-
ables as disease descriptions. For the current implementation,
Clinical Care Groups (a product of Ingenix) was chosen as the
disease description standard. To capture the multifactorial nature
of the relationships, logistic regression was used. The process of
creation of several such models was automated. The models were
evaluated based on standard metrics such as concordance rate,
false positives, sensitivity, etc. Performance of the models rela-
